Control of lipolysis by natriuretic peptides and cyclic GMP.

Max Lafontan; Cédric Moro; Michel Berlan; François Crampes; Coralie Sengenes; Jean Galitzky

doi:10.1016/j.tem.2007.11.006

Control of lipolysis by natriuretic peptides and cyclic GMP.

Max Lafontan ^{1, *} Cédric Moro ¹ Michel Berlan ¹ François Crampes ¹ Coralie Sengenes ¹ Jean Galitzky ¹

* Auteur correspondant

1 I2MR - Institut de médecine moléculaire de Rangueil

Abstract : Human fat cell lipolysis was, until recently, thought to be mediated exclusively by a cAMP-dependent protein kinase (PKA)-regulated pathway under the control of catecholamines and insulin. We have shown that atrial- and B-type natriuretic peptides (ANP and BNP respectively) stimulate lipolysis in human fat cells through a cGMP-dependent protein kinase (PKG) signaling pathway independent of cAMP production and PKA activity. Pharmacological or physiological (exercise) increases in plasma ANP levels stimulate lipid mobilization in humans. This pathway becomes important during chronic treatment with beta-adrenoceptor antagonists, which inhibit catecholamine-induced lipolysis but enhance cardiac ANP release. These findings have metabolic implications and point to potential problems when natriuretic peptide secretion is altered or during therapeutic use of recombinant BNP.

Type de document :

Article dans une revue

Trends in Endocrinology and Metabolism = Trends in Endocrinology & Metabolism , Elsevier, 2006, 19 (4), pp.130-7. 〈10.1016/j.tem.2007.11.006〉

Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00409147
Contributeur : Marie Francoise Simon <>
Soumis le : jeudi 6 août 2009 - 10:37:28
Dernière modification le : jeudi 13 septembre 2018 - 10:26:05

Control of lipolysis by natriuretic peptides and cyclic GMP.

Identifiants

Collections

Citation

Exporter

Métriques

64

Contact

Control of lipolysis by natriuretic peptides and cyclic GMP.

Identifiants

Collections

Citation

Exporter

Partager

Métriques

64

Contact